Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04557098Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Nov 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 11
01
Overview
A Phase 2 trial of teclistamab in multiple myeloma (MM), sponsored by Janssen Pharmaceutical. Started Sep 2020; status: active, not recruiting.
02
Drugs
teclistamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04557098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557098.